ATE361747T1 - Kombinierte verwendung von melatonin und methylphenidat zur behandlung von aufmerksamkeits-/hyperaktivitätsstörungen. - Google Patents

Kombinierte verwendung von melatonin und methylphenidat zur behandlung von aufmerksamkeits-/hyperaktivitätsstörungen.

Info

Publication number
ATE361747T1
ATE361747T1 AT03750659T AT03750659T ATE361747T1 AT E361747 T1 ATE361747 T1 AT E361747T1 AT 03750659 T AT03750659 T AT 03750659T AT 03750659 T AT03750659 T AT 03750659T AT E361747 T1 ATE361747 T1 AT E361747T1
Authority
AT
Austria
Prior art keywords
melatonin
methylphenidate
treatment
combined use
attention
Prior art date
Application number
AT03750659T
Other languages
English (en)
Inventor
Roelof Kruisinga
Original Assignee
Pooger Properties Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pooger Properties Ltd filed Critical Pooger Properties Ltd
Application granted granted Critical
Publication of ATE361747T1 publication Critical patent/ATE361747T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4458Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
AT03750659T 2002-09-26 2003-09-26 Kombinierte verwendung von melatonin und methylphenidat zur behandlung von aufmerksamkeits-/hyperaktivitätsstörungen. ATE361747T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02021810 2002-09-26

Publications (1)

Publication Number Publication Date
ATE361747T1 true ATE361747T1 (de) 2007-06-15

Family

ID=32039113

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03750659T ATE361747T1 (de) 2002-09-26 2003-09-26 Kombinierte verwendung von melatonin und methylphenidat zur behandlung von aufmerksamkeits-/hyperaktivitätsstörungen.

Country Status (8)

Country Link
US (1) US20060167050A1 (de)
EP (1) EP1545511B1 (de)
AT (1) ATE361747T1 (de)
AU (1) AU2003270292A1 (de)
CA (1) CA2500198A1 (de)
DE (1) DE60313785T2 (de)
ES (1) ES2287512T3 (de)
WO (1) WO2004028532A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG185969A1 (en) * 2008-01-31 2012-12-28 Takeda Pharmaceutical Prophylactic or therapeutic agent for attention deficit/hyperactivity disorder
UA107653U (uk) * 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
US5654325A (en) * 1993-11-18 1997-08-05 Eli Lilly And Company Melatonin derivatives for use in treating sleep disorders
US6121261A (en) * 1997-11-19 2000-09-19 Merck & Co., Inc. Method for treating attention deficit disorder
CA2357114C (en) * 2001-03-22 2010-06-29 Pooger Properties Ltd. Use of melatonin in the manufacture of a medicament for treating attention deficit hyperactive disorder

Also Published As

Publication number Publication date
AU2003270292A1 (en) 2004-04-19
US20060167050A1 (en) 2006-07-27
WO2004028532A1 (en) 2004-04-08
ES2287512T3 (es) 2007-12-16
DE60313785T2 (de) 2008-01-24
EP1545511B1 (de) 2007-05-09
CA2500198A1 (en) 2004-04-08
EP1545511A1 (de) 2005-06-29
DE60313785D1 (de) 2007-06-21

Similar Documents

Publication Publication Date Title
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
ATE451376T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
DE60207383D1 (de) Ibuprofen und diphenhydramin enthaltende zusammensetzungen und deren verwendung zur behandlung von schlafstörungen
EA200602062A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
NO20093464L (no) Nye medikamentblandinger basert pa anti-cholinergisk effektive forbindelser og beta-mimetika
NO20070372L (no) Amidoforbindelser og anvendelse derav som farmasoytiske preparater
MXPA05013224A (es) Piridinilcarbamatos como inhibidores de lipasa sensible a hormonas.
ATE464303T1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
ATE337780T1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
NO20052928L (no) Nye kjemiske forbindelser
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
ATE275400T1 (de) Verwendung von melatonin zur behandlung der androgenetischen und diffusen alopezie vom weiblichen typ
NO20082679L (no) Sammensetning og fremgangsmate for a behandle CNS lidelser
ATE542536T1 (de) 3-ä4-(dibenzoäb,füä1,4üoxazepin-11-yl)-piperazi - 1-ylü-2,2-dimethyl propansäure zur verwendung in der behandlung von schlafstörungen
MXPA05013226A (es) Carbamatos de piperidina sustituidos, para el uso como inhibidores de la lipasa sensible a hormonas.
DE502005009908D1 (de) Verwendung von fluoreszierenden perlylenverbindungen zur behandlung menschlicher haare
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ATE361747T1 (de) Kombinierte verwendung von melatonin und methylphenidat zur behandlung von aufmerksamkeits-/hyperaktivitätsstörungen.
NO20071466L (no) 3-substituerte-5- og 6-aminoalkyl indol-2-karboksylsyreamider og relaterte analoger som inhibitorer av kaseinkinase IE
DE60027127D1 (de) Verwendung von Polyaminosäurederivaten zur Behandlung von Seborrhoe und verwandten Hautstörungen
DE60219940D1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1545511

Country of ref document: EP